title: US FDA oncology drug approvals in 2014.
abstract: Cancer is a close second to heart disease for cause of death in the USA, and could soon surpass heart disease as the population ages and the incidence of cancer continues to increase. While heart disease can be addressed through behavior modification and education (e.g., smoking cessation, dietary changes, exercises that promote cardiovascular fitness), pharmacology and improved surgical devices and methods, cancer ultimately requires improved and novel drug treatments to bring mortality rates down. In 2014, the US FDA approved 17 drugs and/or drug combinations in 12 disease sites for a total of 19 indications in melanoma, hematologic malignancies, gastrointestinal carcinoma, non-small-cell lung cancer, gynecologic malignancies and lymphoma/lymphoproliferative disorders.
authors.affiliation: The Chao Family NCI-Designated Comprehensive Cancer Center, University of California, Irvine Medical Center, 101 The City Drive South, Bldg 56, Orange, CA 92868, USA.
authors.forename: Juliet E
authors.initials: JE
authors.lastname: Wolford
authors.affiliation: The Chao Family NCI-Designated Comprehensive Cancer Center, University of California, Irvine Medical Center, 101 The City Drive South, Bldg 56, Orange, CA 92868, USA.
authors.forename: Krishnansu S
authors.initials: KS
authors.lastname: Tewari
mesh_terms: D017277:Drug Approval / Q000266:history / Q000331:legislation & jurisprudence*; D049674:History, 21st Century; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D014481:United States; D014486:United States Food and Drug Administration / Q000266:history / Q000331:legislation & jurisprudence*
keywords: US FDA; accelerated approval; cancer drugs; orphan drug designation; priority review; regulatory approval